Lisocabtagene maraleucel delivers sustained survival benefits and long-term disease control in relapsed or refractory LBCL.

At the surface, the immune response to a flu virus is simple. Some cells recognize the pathogen and send a signal to the ...

Learn more about the research of Mayo Clinic's Gene Editing and Cellular Engineering Laboratory led by David (Chun-Wei) D.

Teclistamab-cqyv (Tecvayli) led to clinically meaningful responses in patients with heavily pretreated multiple myeloma who ...

At the surface, the immune response to a flu virus is simple. Some cells recognize the pathogen and send a signal to the ...

This new article publication from Acta Pharmaceutica Sinica B, discusses how melatonin receptor 1a alleviates sleep fragmentation-aggravated testicular injury in T2DM by suppression of TAB1/TAK1 ...

Allogeneic cell therapies are advancing in clinical trials, requiring oncologists and pathologists to understand the ...

Antibody–siRNA conjugates (ARCs) are a type of promising drug modalities for cancer therapy. However, initial reports of ARCs present the gene knockdown effect only in limited tissues (e.g., muscles) ...

During a live event, Jeffrey V. Matous, MD, discussed bispecific antibody treatment efficacy and safety in advanced multiple ...

Ichnos Glenmark Innovation subsidiary IGI Therapeutics has signed an exclusive licensing agreement with AbbVie for ISB 2001, ...